ClinicalTrials.gg
CompletedNCT06671470Updated Jun 30, 2026

A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects

A Phase 1 interventional study of YZJ-1139 tablets and Ticagrelor Tablets in Insomnia, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
144th of 162
27 · median 88
Started
2024
with 44 others
Phase 1
13 of 198
1 open now
Registered
125th of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 144th largest by enrollment of the 162 interventional ones that give a count, is one of 45 that started in 2024, is one of 13 in phase 1, and was the 125th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

Primary Objective :

To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects;

Secondary Objective:

To evaluate the safety of ticagrelor tablets in combination with YZJ-1139 tablets in healthy subjects.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able to understand and are willing to strictly follow the clinical trial protocol to complete this trial and sign the form; 2) Male and female subjects aged 18\~45 years (including cut-off value); 3) Male weight ≥ 50.0kg, female weight ≥ 45.0kg, (BMI) within the range of 19.0\~26.0kg/m2 (including the cut-off value); 4) normal or abnormal physical examination, vital signs, 12-lead , laboratory tests are not ; 5) Good health, those who with no respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, psychiatric system history of serious and chronic diseases; 6) Subjects (including partners) have no fertility plan, sperm/egg donation plan and voluntarily use adequate from signing informed consent and within 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Allergies: Those with a history of two or more drug or food allergies in the past; or those who are known to be allergic to YZJ-1139 tablets and test concomitant drugs and ;
  2. Those who have difficulty swallowing tablets, or those who have special dietary requirements and cannot accept the standard diet provided by the research center;
  3. Those who cannot tolerate venipuncture, or have a history of fainting blood or needles;
  4. Those who have a history or current narcolepsy, obstructive sleep apnea, complex sleep behaviors (such as sleepwalking, dream driving, etc.), severe unconscious hypoglycemia, stroke, epilepsy and other psychiatric neurological diseases (including anxiety, depression, etc.), convulsive diseases, cataplexy;
  5. Those with bleeding tendency (such as recent trauma, recent surgery, coagulation dysfunction, active or recent intestinal bleeding), have a history of active pathological bleeding, intracranial hemorrhage, or other diseases that can change or increase bleeding tendency (peptic ulcer, Henoch-Schonlein purpura, lupus erythematosus, etc.);
  6. Those who with abnormal clinical significance in the determination of surface antigen, virus antibody, hepatitis C virus core antigen, (HIV) antigen antibody combined detection, and treponema pallidum specific antibody determination;
  7. Regular drinkers within 6 months prior to screening, i.e., drinking an average of more than 14 units of alcohol per week (1 unit ≈ 360mL of beer or 45mL of spirits with 40% alcohol or 150mL of wine) or > alcohol breath test results during the screening period0mg/100mL;
  8. Those who have used soft drugs (such as marijuana) within 3 months before screening or taken hard drugs (such as cocaine, amphetamines, phencyclidine ) within 1 year before screening; or those with a history of substance abuse; or those who have a positive drug abuse screen at screening;
  9. Those who have smoked ≥5 cigarettes per day within 3 months before screening or cannot stop using any tobacco products during the trial;
  10. Those who have donated blood or lost a large amount of blood (> 400mL) within 3 months prior to screening, received blood transfusion or used blood products;
  11. Those who have participated in any clinical trial and been given drugs or investigational medical devices within 3 months prior to screening; or those who plan to participate in other clinical trials during the study period;
  12. Those who have undergone surgical procedures within 30 days prior to screening, or who plan to undergo surgical procedures during the study;
  13. Received vaccination within 30 days prior to screening, or planned vaccination during the trial;
  14. Use of any drug that inhibits or induces hepatic metabolism of the drug within 28 days prior to screening (e.g.: inducers-barbiturates, carbamazepine, phenytoin, , omeprazole; Inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines);
  15. Those who have taken any prescription drugs, over-the-counter drugs, health products, vitamins, or Chinese herbal medicines within 14 days before screening;
  16. Consumption of grapefruit, pomelo, dragon fruit, mango and other fruits or related products that affect metabolic enzymes within 7 days before screening;
  17. Intake of caffeine- or xanthine-rich beverages or foods (such as coffee, strong tea, chocolate, cola, etc.) within 24 hours before administration;
  18. Female subjects who are lactating or have a positive pregnancy result;
  19. Those who have sudden acute illness or new concomitant medication from the screening stage to before enrollment;
  20. In the opinion of the investigator, the subject is not suitable for inclusion in this trial for other reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Group A

    Drug: YZJ-1139 tablets · Drug: Ticagrelor Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of YZJ-1139(Cmax)

    To evaluate the potential effect of multiple oral doses of ticagrelor on the single-dose PK of YZJ-1139. Maximum observed concentration (Cmax).

    Time frame: 48 hours

  2. Pharmacokinetics of YZJ-1139 (AUC0-∞)

    To evaluate the potential effect of multiple oral doses of ticagrelor on the single-dose PK of YZJ-1139. Area under the concentration-time curve (AUC) from time zero to infinity.

    Time frame: 48 hours

  3. Pharmacokinetics of YZJ-1139 (AUC0-t)

    To evaluate the potential effect of multiple oral doses of ticagrelor on the single-dose PK of YZJ-1139. Area under the concentration-time curve (AUC) time zero to last quantifiable concentration.

    Time frame: 48 hours

Secondary outcomes

  1. Number of participants with adverse events

    The safety and tolerability of YZJ-1139 alone and in combination with ticagrelor will be examined.

    Time frame: 13 days

07

Study locations

1 site
  • Shulan (Hangzhou) Hospital
    Huangzhou, China
08

References and documents

Publications

  • Huang X, Chen Y, Jin L, Kong Y, Bao F, Wang R. Drug-drug interaction between ticagrelor and fazamorexant: pharmacokinetic alterations in healthy subjects from a phase I, open-label, fixed-sequence study. BMC Pharmacol Toxicol. 2026 Jul 22. doi: 10.1186/s40360-026-01186-0. Online ahead of print. PubMed 42482263 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Sep 2024, 0 months.

Of 23 industry-sponsored phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 1 and three quarters within 5. This study's 0 months is below that.

Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 4, 2024
StartActual
Aug 22, 2024
Primary completionActual
Sep 13, 2024
CompletionActual
Oct 15, 2024
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06671470
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Aug 22, 2024
Primary completion
Sep 13, 2024
Completion
Oct 15, 2024
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fazamorexant · Ticagrelor

Start the discussion